2024年4月至7月在西澳大利亚州对儿童使用尼塞韦单抗进行的上市后主动安全性监测

ACTIVE POST-MARKETING SAFETY SURVEILLANCE OF NIRSEVIMAB ADMINISTERED TO CHILDREN IN WESTERN AUSTRALIA, APRIL-JULY 2024.

作者信息

Carcione Dale, Spencer Phoebe, Pettigrew Grace, Leeb Alan, Drake-Brockman Carla, Ford Timothy, Effler Paul

机构信息

From the Communicable Disease Control Directorate, Western Australia Department of Health, Perth, Western Australia, Australia.

Illawarra Medical Centre, Perth, Western Australia, Australia.

出版信息

Pediatr Infect Dis J. 2025 Jan 3. doi: 10.1097/INF.0000000000004715.

DOI:10.1097/INF.0000000000004715

PMID:39773919

Abstract

Children receiving nirsevimab were texted a link to an online survey to monitor adverse events following immunization. Total of 4340 parents received the link, which 1195 (27.5%) responded. Forty-seven (11.4%) of 410 children who received nirsevimab alone and 230 (29.3%) of 785 children who received nirsevimab coadministered reported any reaction. No adverse events required in-patient care or had ongoing sequelae.

摘要

接受尼塞韦单抗的儿童会收到一条指向在线调查的链接，以监测免疫接种后的不良事件。共有4340名家长收到该链接，其中1195名（27.5%）做出了回应。仅接受尼塞韦单抗的410名儿童中有47名（11.4%），接受尼塞韦单抗联合给药的785名儿童中有230名（29.3%）报告了任何反应。没有不良事件需要住院治疗或有持续的后遗症。